Jim Simons’s Janux Therapeutics JANX Stock Holding History

Jim Simons’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-92,899	Closed	-$3.5M	–	3745
2024 Q1	$3.5M	Buy	+92,899	New	+$2.02M	0.01%	1650
2023 Q4	–	Sell	-26,100	Closed	-$263K	–	3923
2023 Q3	$263K	Buy	26,100 +11,300	+76%	+$130K	﹤0.01%	2994
2023 Q2	$176K	Buy	+14,800	New	+$198K	﹤0.01%	3331

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jim Simons's JANX Position: Q2 2024 in Review

Jim Simons sold out of Janux Therapeutics (JANX) in Q2 2024, closing a stake of 92,899 shares — an estimated $3.5M sold.

Jim Simons first reported a position in JANX in Q2 2023 and held it in 3 quarters. The position peaked at $3.5M in Q1 2024. 155 funds tracked by Wall St. Rank hold JANX as of Q2 2024.

Jim Simons reported no remaining Janux Therapeutics position as of Q2 2024 after selling out during the quarter.
Jim Simons sold 92,899 Janux Therapeutics shares in Q2 2024, an estimated $3.5M.
Jim Simons first reported a position in Janux Therapeutics in Q2 2023 and held it in 3 quarters.
Jim Simons's Janux Therapeutics position peaked at $3.5M in Q1 2024.
155 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2024.

Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.